Strides Pharma Science is currently trading at Rs. 854.90, up by 8.75 points or 1.03% from its previous closing of Rs. 846.15 on the BSE.

The scrip opened at Rs. 846.75 and has touched a high and low of Rs. 856.30 and Rs. 841.25 respectively. So far 4887 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 914.00 on 06-May-2024 and a 52 week low of Rs. 346.40 on 25-May-2023.

Last one week high and low of the scrip stood at Rs. 882.80 and Rs. 840.70 respectively. The current market cap of the company is Rs. 7818.76 crore.

The promoters holding in the company stood at 25.88%, while Institutions and Non-Institutions held 42.62% and 31.50% respectively.

Strides Pharma Science’s step-down wholly owned subsidiary -- Strides Pharma Global, Singapore, has received approval for the generic version of Sucralfate Oral Suspension, 1gm/10 mL, from the United States Food & Drug Administration (USFDA).

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Carafate 1gm/10mL of AbbVie. Sucralfate is used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers. Sucralfate Oral Suspension, 1gm/10 mL has a market size of around $124 million as per IQVIA (March 2024). The Sucralfate Oral Suspension, 1gm/10 mL will be manufactured at the company’s flagship facility in KRS Gardens in Bangalore, India.

The company has 260 cumulative ANDA filings (including the acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 245+ ANDAs have been approved. The company has set a target to launch around 60 new products over three years in the US. 

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.